| Literature DB >> 25751686 |
Ying Li1,2, Jie Xuan3, Tom Xia1, Xin Han1,2, Yujun Song1,2, Zheng Cao3, Xin Jiang4, Yi Guo5, Ping Wang3, Lidong Qin1,2.
Abstract
Point-of-care (POC) testing has become widely used in clinical analysis because of its speed and portability; however, POC tools, such as lateral flow assays, suffer from low specificity, unclear readouts, and susceptibility to environmental and user errors. Herein, we report an ELISA-based competitive volumetric bar-chart chip (CV-chip) that eliminates these limitations. The CV-chip displays the readout in the form of ink bar charts based on direct competition between gases generated by the sample and the internal control. By employing a "competition mode", this platform decreases the potential influence of background resulting from environmental factors and provides visually clear positive or negative results without the requirement of calibration. In addition, the on-chip comparison enables the device to distinguish imperceptible differences (less than 1.3-fold) in human chorionic gonadotropin (hCG) concentrations that are near the cutoff value for pregnancy (∼1.4 ng/mL). We also utilized the ELISA-based CV-chip to successfully detect biomarkers from cancer cells. As a proof-of-concept application in a clinical setting, the CV-chip was employed to evaluate the status of drugs of abuse in 18 patients. For six different drugs, zero false-positive and very few false-negative (<2%) results were reported in more than 100 tests. This new ELISA platform offers a clinical diagnostics tool that is portable and easy to use, and provides improved clarity and sensitivity due to the inclusion of a real-time internal control.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25751686 PMCID: PMC4631400 DOI: 10.1021/ac504301y
Source DB: PubMed Journal: Anal Chem ISSN: 0003-2700 Impact factor: 6.986